ATRC Sees 16-20% Revenue Growth, RIGL On Watch, LUNG Breathes Easy, BPMC Braces For Busy Year

Kymera Therapeutics Inc. (KYMR), a clinical-stage biopharmaceutical company developing targeted protein degradation to deliver novel small molecule protein degrader medicines, looks ahead to sharing data from its two oncology programs, KT-413 and KT-333, in the second half of this year.

from RTT - Top Story https://ift.tt/pZmFhEv
via IFTTT